(Q24234975)

English

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma (English)

0 references

0 references

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

4

0 references

2

0 references

3

0 references

Corinne Brillant

5

0 references

1

object named as

Kathrin Bauer

0 references

publication date

10 August 2011

0 references

Cochrane Database of Systematic Reviews

0 references

Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Chemotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Is BEACOPP better than ABVD?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Current clinical trials for advanced Hodgkin's lymphoma in North America: history, design and rationale

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Hodgkin's disease--clinical trials and travails

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Current clinical trials for the treatment of adult advanced-stage Hodgkin's disease: GELA experiences. Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

State-of-the-art therapeutics: Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Addressing Reporting Biases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Epidemiology and etiology of Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Analysing Data and Undertaking Meta-Analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

21 January 2018

Phase 3 trials suggest ways to improve current hematologic cancer therapies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

The case for and against high-dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

An international approach to the treatment of Hodgkin's disease in the elderly: launch of the SHIELD study programme.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

The EORTC strategy in the treatment of Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adult

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007941.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD007941.PUB2

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24234975&oldid=1742034117"